Long Alison S 4

What Happened

• Alison S. Long, a director of Taysha Gene Therapies (TSHA), received equity awards on 2026-06-01 consisting of two RSU grants: 21,335 shares (reported as A) and 42,671 shares (reported as A, derivative), for a total of 64,006 restricted stock units. Each grant was reported at $0.00 per share on the Form 4 (typical for RSU awards at grant).

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-02 (timely).
• Grant types/codes: A (award/grant); one entry is labeled “derivative” but both footnotes indicate these are RSU awards.
• Share counts and price: 21,335 RSUs @ $0.00 and 42,671 RSUs (derivative) @ $0.00; total 64,006 RSUs.
• Vesting: RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person’s continued service as a director (footnotes F1 and F2).
• Shares owned after transaction: not stated in the provided filing.
• Filing timeliness: filed the next day (appears timely; not marked late).

Context

• These are restricted stock units (RSUs), meaning they represent a promise to issue common shares in the future once vesting conditions are met — they are not immediate open‑market purchases or sales. Director RSU grants are common as compensation for board service and do not by themselves indicate a buy or sell signal; value is realized only if and when the RSUs vest and convert to shares.